Deinove S.A. (DNVVF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Deinove S.A. (DNVVF) trades at $0.50 with AI Score 44/100 (Grade C). Deinove S. A. is a French biotech company focused on discovering, developing, and producing microbially-derived compounds for the health, nutrition, and cosmetics industries. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for DNVVF: DNVVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DNVVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DNVVF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Deinove S.A. (DNVVF) Healthcare & Pipeline Overview
Deinove S.A. is a biotechnology company specializing in the discovery and development of microbial-based compounds for the health, nutrition, and cosmetics sectors. With a focus on innovative solutions like antibiotic candidates and active cosmetic ingredients, Deinove aims to address unmet needs in diverse markets through strategic partnerships and proprietary technology.
What Is the Investment Thesis for DNVVF?
Deinove S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead antibiotic candidate, DNV3837, targeting Clostridioides difficile infections, represents a significant potential value driver, contingent on successful Phase II and subsequent clinical trials. The growing market for natural and sustainable cosmetic ingredients also offers revenue diversification. However, the company's negative profit margin of -1904.9% and gross margin of -904.1% highlight the need for substantial revenue growth and cost management. Investors should closely monitor clinical trial outcomes, partnership developments, and the company's ability to secure additional funding to support its operations and research pipeline. The company's beta of 0.35 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
DNVVF Key Highlights
DNV3837 is in Phase II clinical trials for Clostridioides difficile infections, representing a key potential value driver.
- Offers a range of active ingredients for the cosmetics industry, including PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif.
- Partnerships with bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril provide access to expertise and resources.
- Negative profit margin of -1904.9% indicates significant challenges in achieving profitability.
- Beta of 0.35 suggests lower volatility compared to the overall market.
Who Are DNVVF's Competitors?
DNVVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.5M | 46 |
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.6M | 57 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.7M | 44 |
| KMSTF Kadimastem Ltd | $3.21 | -3.02% | $9.50M | 44 |
| NOXOF Noxopharm Limited | $0.04 | +0.00% | $14.8M | 43 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DNVVF's Key Strengths?
Innovative microbial-based technology platform.
- Diverse product pipeline targeting multiple markets.
- Strategic partnerships with established companies.
- Expertise in developing natural and sustainable ingredients.
What Are DNVVF's Weaknesses?
Negative profit and gross margins.
- Reliance on external funding.
- High R&D costs and long development timelines.
- Limited commercialization capabilities.
What Could Drive DNVVF Stock Higher?
DNVVF catalyst: Results from Phase II clinical trials for DNV3837 in the treatment of Clostridioides difficile infections.
- Development and commercialization of new active ingredients for the cosmetics industry.
- Expansion of partnerships with companies in the healthcare, nutrition, and cosmetics industries.
- Securing additional funding through grants, equity financing, or debt financing.
- Progress in the development of microbial-based solutions for animal feed.
What Are the Key Risks for DNVVF?
Failure of DNV3837 in clinical trials.
- Competition from larger pharmaceutical and cosmetic companies.
- Regulatory hurdles and delays in product approvals.
- Negative profit and gross margins.
- Reliance on external funding.
What Are the Growth Opportunities for DNVVF?
- Growth opportunity 1: Successful completion of Phase II clinical trials for DNV3837 and subsequent advancement to Phase III could unlock significant value in the Clostridioides difficile infection (CDI) treatment market. Positive clinical data could lead to partnerships with larger pharmaceutical companies for commercialization and distribution.
- Growth opportunity 2: Expansion of the cosmetics active ingredients portfolio and penetration of new geographic markets represents a significant growth opportunity. The global market for natural and sustainable cosmetic ingredients is experiencing rapid growth, driven by consumer demand for clean beauty products. Deinove can leverage its existing portfolio and develop new ingredients to capture a larger share of this market. Geographic expansion into Asia and North America could further accelerate growth.
- Growth opportunity 3: Development of new microbial-based solutions for animal feed offers a diversification opportunity. The animal feed market is a large and growing market, driven by increasing demand for meat and animal products. Deinove can leverage its expertise in microbial fermentation to develop natural and sustainable ingredients for animal feed, addressing the growing demand for alternatives to traditional feed additives.
- Growth opportunity 4: Strategic partnerships and collaborations with other companies in the healthcare, nutrition, and cosmetics industries can accelerate the development and commercialization of Deinove's products. Partnerships can provide access to expertise, resources, and distribution channels. Deinove has a history of successful partnerships and can continue to leverage this strategy to drive growth.
- Growth opportunity 5: Securing additional funding through grants, equity financing, or debt financing is crucial for supporting Deinove's research and development activities. The biotechnology industry is capital-intensive, and companies need access to funding to advance their product pipelines. Deinove's ability to secure additional funding will be a key factor in its long-term success.
What Threats Does DNVVF Face?
- Competition from larger pharmaceutical and cosmetic companies.
- Regulatory hurdles and clinical trial failures.
- Patent expiration and generic competition.
- Economic downturns and reduced consumer spending.
What Are DNVVF's Competitive Advantages?
- Proprietary microbial library and screening platform.
- Expertise in developing and producing microbial-based compounds.
- Patent protection for its key technologies and products.
- Established partnerships with leading companies in the healthcare, nutrition, and cosmetics industries.
What Does DNVVF Do?
Founded in 2006 and headquartered in Grabels, France, DEINOVE SA is a biotech company dedicated to leveraging the power of microbial biodiversity to create innovative solutions for the health, nutrition, and cosmetics industries. The company's core expertise lies in discovering, developing, and producing high-value compounds derived from microorganisms, particularly extremophilic bacteria called Deinococcus. Deinove's initial focus was on biofuels but has since pivoted to higher-margin applications in healthcare and cosmetics. Deinove's product pipeline includes DNV3837, an antibiotic currently in Phase II clinical trials for the treatment of Clostridioides difficile infections (CDI). In the cosmetics sector, Deinove offers a range of active ingredients, including PHYT-N-Resist (an anti-aging ingredient), Luminity (a carotenoid-based ingredient for blue light absorption and antioxidant properties), HEBELYS (a natural active ingredient produced by fermentation), and BIOME Oléoactif (a post-biotic extract with a prebiotic effect). The company also develops processes for producing natural ingredients for animal feed. Deinove collaborates with various partners, including bioMérieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Oléos-Hallstar, Greentech, and Avril, to advance its research and commercialization efforts.
What Products and Services Does DNVVF Offer?
- Discovers and develops compounds from microbials.
- Produces ingredients for the health industry.
- Creates ingredients for the nutrition industry.
- Develops ingredients for the cosmetics industry.
- Offers an antibiotic candidate (DNV3837) for Clostridioides difficile infections.
- Provides anti-aging active ingredients for cosmetics (PHYT-N-Resist).
- Offers a carotenoid-based ingredient for blue light absorption (Luminity).
- Develops natural active ingredients produced by fermentation (HEBELYS).
How Does DNVVF Make Money?
- Develops and patents novel microbial-based compounds.
- Out-licenses or partners with larger companies for commercialization of its products.
- Generates revenue through sales of active ingredients to cosmetic companies.
- Seeks strategic partnerships to fund and advance its drug development programs.
What Industry Does DNVVF Operate In?
Deinove operates in the competitive biotechnology industry, characterized by high R&D costs, lengthy development timelines, and regulatory hurdles. The company focuses on niche markets within healthcare (antibiotics) and cosmetics (active ingredients). The global antibiotics market is driven by increasing antibiotic resistance, while the demand for natural and sustainable cosmetic ingredients is fueled by consumer preferences for clean beauty products. Deinove competes with larger pharmaceutical and cosmetic companies, as well as specialized biotech firms. Success depends on scientific innovation, clinical trial outcomes, and effective commercialization strategies.
Who Are DNVVF's Key Customers?
- Cosmetic companies seeking innovative and natural active ingredients.
- Pharmaceutical companies interested in licensing or acquiring novel antibiotic candidates.
- Animal feed manufacturers looking for natural and sustainable feed additives.
- Consumers who purchase products containing Deinove's ingredients.
Company Profile
Deinove S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Grabels, FR. The company is led by CEO Alexis Rideau. DNVVF has traded publicly since 2013.
Deinove S.A. (DNVVF) Valuation Context
Relative to its peer group, DNVVF's quantitative score of 44/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Return on equity for Deinove S.A. stands at 60.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -74.6%, showing how much profit it generates from its asset base. A current ratio of 1.36 indicates the company holds enough short-term assets to cover its near-term obligations.
DNVVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Deinove's focus on rare carotenoids is gaining traction, with potential applications in nutraceuticals and cosmetics, mirroring the early interest in Beyond Meat's plant-based protein.
- Positive community sentiment suggests growing investor belief in Deinove's technology platform for sustainable ingredient production, similar to the buzz around Ginkgo Bioworks' synthetic biology capabilities.
- Recent insider activity indicates confidence in the company's long-term prospects, which can be a positive signal, much like when Elon Musk buys Tesla shares.
- The market is increasingly valuing companies with sustainable and bio-based solutions, positioning Deinove favorably in the current investment climate, similar to the shift towards renewable energy stocks.
Bear Case
- Limited market awareness of Deinove's specific applications and potential revenue streams compared to established players in the ingredient market, akin to the challenges faced by smaller biotech firms against pharmaceutical giants.
- Community skepticism about Deinove's ability to scale production and compete effectively in the global carotenoid market, similar to concerns about smaller EV companies challenging Tesla's dominance.
- Bearish community views highlight concerns about the company's financial stability and ability to secure future funding, reminiscent of worries surrounding companies with high burn rates.
- Uncertainty surrounding regulatory approvals and market acceptance of Deinove's novel ingredients may delay commercialization and impact investor confidence, similar to the regulatory hurdles faced by gene editing companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DNVVF Latest News
No recent news available for DNVVF.
DNVVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DNVVF.
Price Targets
Wall Street price target analysis for DNVVF.
DNVVF MoonshotScore
What does this score mean?
The MoonshotScore rates DNVVF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alexis Rideau
CEO
Alexis Rideau serves as the CEO of Deinove S.A. His background includes experience in the biotechnology and pharmaceutical industries, with a focus on strategic development and commercialization. He has held various leadership positions in companies focused on healthcare innovation. Rideau's expertise spans areas such as business development, product strategy, and market access. His educational background includes advanced degrees in science and business administration, providing a strong foundation for leading a biotech company.
Track Record: Under Alexis Rideau's leadership, Deinove S.A. has focused on advancing its product pipeline, particularly the DNV3837 antibiotic candidate. He has overseen the progression of DNV3837 through clinical trials and has worked to secure partnerships to support the company's research and development efforts. Rideau has also directed the expansion of Deinove's cosmetics active ingredients portfolio and the exploration of new market opportunities.
DNVVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Deinove S.A. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to increased risk for investors due to potential lack of transparency and oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher risk of fraud or manipulation.
- Lower liquidity and wider bid-ask spreads.
- Potential for delisting or trading suspension.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's products, services, and market position.
- Understand the company's capital structure and ownership.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Partnerships with reputable companies (e.g., bioMérieux, Hallstar Group).
- Advancement of DNV3837 through clinical trials.
- Development of a portfolio of active ingredients for the cosmetics industry.
- Presence of a management team with experience in the biotechnology industry.
- Scientific publications or presentations related to the company's technology.
Common Questions About DNVVF (Healthcare)
What does the AI Score mean for DNVVF?
DNVVF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Deinove S.A. is a French biotech company focused on discovering, developing, and producing microbially-derived compounds for the health, nutrition, and cosmetics industries. Their pipeline includes …
What does Deinove S.A. do?
Deinove S.A. is a biotechnology company that specializes in discovering, developing, and producing compounds originating from microorganisms. Their primary focus is on creating innovative solutions for the health, nutrition, and cosmetics industries.
What do analysts say about DNVVF stock?
As of March 18, 2026, there is no readily available analyst consensus on DNVVF stock due to its OTC listing and limited coverage. Key valuation metrics, such as the P/E ratio of -0.11, reflect the company's current lack of profitability. Growth considerations revolve around the successful development and commercialization of DNV3837 and the expansion of its cosmetics active ingredients portfolio.
What are the main risks for DNVVF?
The main risks for Deinove S.A. include the potential failure of DNV3837 in clinical trials, which would significantly impact the company's value. Competition from larger pharmaceutical and cosmetic companies with greater resources poses a threat. Regulatory hurdles and delays in product approvals could also impede progress. The company's negative profit and gross margins highlight the financial challenges it faces.
What are the key factors to evaluate for DNVVF?
Deinove S.A. (DNVVF) holds an AI score of 44/100 (low). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does DNVVF data refresh on this page?
DNVVF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DNVVF's recent stock price performance?
Deinove S.A. (DNVVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative microbial-based technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DNVVF overvalued or undervalued right now?
Deinove S.A. (DNVVF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research DNVVF before investing?
Before investing in Deinove S.A. (DNVVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.